back
SEDI Insider filing browser
| Date | Issuer | Insider | Transaction | Amount | New Balance ⓘ
The balance of securities held by registered holder at the time of the transaction. Insiders may direct multiple registered holders and hold multiple security types.
|
|
|---|---|---|---|---|---|---|
| Filed 2024-03-07 16:31 Tx date 2024-03-07 |
$ATE
Antibe Therapeutics Inc. |
Curtis, Scott Wilson
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$7,800
+15,000 vol $0.52 each |
115,000 | |
| Filed 2023-09-15 18:05 Tx date 2023-09-12 |
$ATE
Antibe Therapeutics Inc. |
Curtis, Scott Wilson
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+136,000 vol |
248,000 | |
| Filed 2022-11-19 12:20 Tx date 2022-11-15 |
$ATE
Antibe Therapeutics Inc. |
Curtis, Scott Wilson
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+42,000 vol |
112,000 | |
| Filed 2022-11-16 19:50 Tx date 2022-11-15 |
$ATE
Antibe Therapeutics Inc. |
Curtis, Scott Wilson
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$10,000
+20,000 vol $0.50 each |
100,000 | |
| Filed 2022-07-12 19:47 Tx date 2022-07-08 |
$ATE
Antibe Therapeutics Inc. |
Curtis, Scott Wilson
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$12,400
+20,000 vol $0.62 each |
80,000 | |
| Filed 2021-11-19 20:47 Tx date 2021-11-15 |
$ATE
Antibe Therapeutics Inc. |
Curtis, Scott Wilson
5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Share Units
56 - Grant of rights
|
+30,000 vol |
245,700 | |
| Filed 2021-11-01 13:37 Tx date 2021-11-01 |
$ATE
Antibe Therapeutics Inc. |
Curtis, Scott Wilson
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$11,440
+13,000 vol $0.88 each |
60,000 | |
| Filed 2021-08-05 18:06 Tx date 2021-08-05 |
$ATE
Antibe Therapeutics Inc. |
Curtis, Scott Wilson
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$3,240
+3,000 vol $1.08 each |
47,000 | |
| Filed 2021-08-05 18:05 Tx date 2021-08-05 |
$ATE
Antibe Therapeutics Inc. |
Curtis, Scott Wilson
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$7,420
+7,000 vol $1.06 each |
44,000 | |
| Filed 2021-07-15 20:20 Tx date 2021-07-14 |
$ATE
Antibe Therapeutics Inc. |
Curtis, Scott Wilson
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$8,892
+2,600 vol $3.42 each |
37,000 | |
| Filed 2021-07-04 17:24 Tx date 2021-06-30 |
$ATE
Antibe Therapeutics Inc. |
Curtis, Scott Wilson
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$12,985
+3,500 vol $3.71 each |
34,400 | |
| Filed 2021-01-15 17:45 Tx date 2021-01-11 |
$ATE
Antibe Therapeutics Inc. |
Curtis, Scott Wilson
5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Share Units
56 - Grant of rights
|
+102,700 vol |
215,700 | |
| Filed 2020-12-17 18:08 Tx date 2020-12-01 |
$ATE
Antibe Therapeutics Inc. |
Curtis, Scott Wilson
5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Share Units
37 - Stock split or consolidation
|
-1,017,000 vol |
113,000 | |
| Filed 2020-12-17 18:06 Tx date 2020-12-01 |
$ATE
Antibe Therapeutics Inc. |
Curtis, Scott Wilson
5 - Senior Officer of Issuer
Direct Ownership
|
Options
37 - Stock split or consolidation
|
-630,000 vol |
70,000 | |
| Filed 2020-12-17 18:05 Tx date 2020-12-01 |
$ATE
Antibe Therapeutics Inc. |
Curtis, Scott Wilson
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
37 - Stock split or consolidation
|
-278,100 vol |
30,900 | |
| Filed 2020-09-22 13:59 Tx date 2020-09-21 |
$ATE
Antibe Therapeutics Inc. |
Curtis, Scott Wilson
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$10,500
+30,000 vol $0.35 each |
309,000 | |
| Filed 2020-06-06 14:16 Tx date 2020-06-05 |
$ATE
Antibe Therapeutics Inc. |
Curtis, Scott Wilson
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
54 - Exercise of warrants
|
$4,950
+33,000 vol $0.15 each |
279,000 | |
| Filed 2020-06-06 14:15 Tx date 2020-06-05 |
$ATE
Antibe Therapeutics Inc. |
Curtis, Scott Wilson
5 - Senior Officer of Issuer
Direct Ownership
|
Warrants
54 - Exercise of warrants
|
$-4,950
-33,000 vol $0.15 each |
0 | |
| Filed 2020-06-06 14:12 Tx date 2020-06-03 |
$ATE
Antibe Therapeutics Inc. |
Curtis, Scott Wilson
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-14,640
-24,000 vol $0.61 each |
246,000 | |
| Filed 2020-06-06 14:10 Tx date 2020-06-01 |
$ATE
Antibe Therapeutics Inc. |
Curtis, Scott Wilson
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-125,000
-200,000 vol $0.63 each |
270,000 | |
| Filed 2020-06-06 14:09 Tx date 2020-06-01 |
$ATE
Antibe Therapeutics Inc. |
Curtis, Scott Wilson
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
51 - Exercise of options
|
$21,750
+150,000 vol $0.145 each |
470,000 | |
| Filed 2020-06-06 14:07 Tx date 2020-06-01 |
$ATE
Antibe Therapeutics Inc. |
Curtis, Scott Wilson
5 - Senior Officer of Issuer
Direct Ownership
|
Options
51 - Exercise of options
|
$-21,750
-150,000 vol $0.145 each |
700,000 | |
| Filed 2019-11-28 13:29 Tx date 2019-11-28 |
$ATE
Antibe Therapeutics Inc. |
Curtis, Scott Wilson
5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Share Units
56 - Grant of rights
|
+400,000 vol |
1,130,000 | |
| Filed 2019-05-17 12:23 Tx date 2019-05-17 |
$ATE
Antibe Therapeutics Inc. |
Curtis, Scott Wilson
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$7,000
+20,000 vol $0.35 each |
320,000 | |
| Filed 2018-10-05 Tx date 2018-10-03 |
$ATE
Antibe Therapeutics Inc. |
Curtis, Scott Wilson
5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Share Units
97 - Other
|
+730,000 vol |
730,000 | |
| Filed 2018-10-05 Tx date 2016-01-01 |
$ATE
Antibe Therapeutics Inc. |
Curtis, Scott Wilson
5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Share Units
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2018-09-19 Tx date 2018-09-18 |
$ATE
Antibe Therapeutics Inc. |
Curtis, Scott Wilson
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$13,000
+50,000 vol $0.26 each |
300,000 | |
| Filed 2018-03-26 Tx date 2018-03-23 |
$ATE
Antibe Therapeutics Inc. |
Curtis, Scott Wilson
5 - Senior Officer of Issuer
Direct Ownership
|
Warrants
54 - Exercise of warrants
|
$-11,000
-50,000 vol $0.22 each |
33,000 | |
| Filed 2018-03-26 Tx date 2018-03-23 |
$ATE
Antibe Therapeutics Inc. |
Curtis, Scott Wilson
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
54 - Exercise of warrants
|
$11,000
+50,000 vol $0.22 each |
250,000 | |
| Filed 2018-03-24 Tx date 2018-03-20 |
$ATE
Antibe Therapeutics Inc. |
Curtis, Scott Wilson
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-42,240
-66,000 vol $0.64 each |
200,000 | |
| Filed 2018-03-24 Tx date 2018-03-20 |
$ATE
Antibe Therapeutics Inc. |
Curtis, Scott Wilson
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-16,250
-25,000 vol $0.65 each |
241,000 | |
| Filed 2018-03-24 Tx date 2018-03-20 |
$ATE
Antibe Therapeutics Inc. |
Curtis, Scott Wilson
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
-91,000 vol |
||
| Filed 2018-03-23 Tx date 2018-03-20 |
$ATE
Antibe Therapeutics Inc. |
Curtis, Scott Wilson
5 - Senior Officer of Issuer
Direct Ownership
|
Warrants
54 - Exercise of warrants
|
$-3,750
-25,000 vol $0.15 each |
83,000 | |
| Filed 2018-03-23 Tx date 2018-03-20 |
$ATE
Antibe Therapeutics Inc. |
Curtis, Scott Wilson
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
54 - Exercise of warrants
|
$3,750
+25,000 vol $0.15 each |
200,000 | |
| Filed 2018-03-23 Tx date 2018-03-20 |
$ATE
Antibe Therapeutics Inc. |
Curtis, Scott Wilson
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
-91,000 vol |
175,000 | |
| Filed 2017-06-24 Tx date 2017-06-21 |
$ATE
Antibe Therapeutics Inc. |
Curtis, Scott Wilson
5 - Senior Officer of Issuer
Direct Ownership
|
Warrants
15 - Acquisition or disposition under a prospectus
|
$3,300
+33,000 vol $0.10 each |
108,000 | |
| Filed 2017-06-24 Tx date 2017-06-21 |
$ATE
Antibe Therapeutics Inc. |
Curtis, Scott Wilson
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
15 - Acquisition or disposition under a prospectus
|
$6,600
+66,000 vol $0.10 each |
266,000 | |
| Filed 2017-04-03 Tx date 2017-03-31 |
$ATE
Antibe Therapeutics Inc. |
Curtis, Scott Wilson
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$80,000
+400,000 vol $0.20 each |
850,000 | |
| Filed 2016-12-16 Tx date 2016-12-15 |
$ATE
Antibe Therapeutics Inc. |
Curtis, Scott Wilson
5 - Senior Officer of Issuer
Direct Ownership
|
Warrants
16 - Acquisition or disposition under a prospectus exemption
|
$7,500
+50,000 vol $0.15 each |
75,000 | |
| Filed 2016-12-16 Tx date 2016-12-15 |
$ATE
Antibe Therapeutics Inc. |
Curtis, Scott Wilson
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
$15,000
+100,000 vol $0.15 each |
200,000 | |
| Filed 2016-06-14 Tx date 2016-06-10 |
$ATE
Antibe Therapeutics Inc. |
Curtis, Scott Wilson
5 - Senior Officer of Issuer
Direct Ownership
|
Warrants
16 - Acquisition or disposition under a prospectus exemption
|
$2,500
+25,000 vol $0.10 each |
25,000 | |
| Filed 2016-06-14 Tx date 2016-06-10 |
$ATE
Antibe Therapeutics Inc. |
Curtis, Scott Wilson
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
$5,000
+50,000 vol $0.10 each |
100,000 | |
| Filed 2016-03-29 Tx date 2016-03-29 |
$ATE
Antibe Therapeutics Inc. |
Curtis, Scott Wilson
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$2,535
+19,500 vol $0.13 each |
50,000 | |
| Filed 2016-03-29 Tx date 2016-03-28 |
$ATE
Antibe Therapeutics Inc. |
Curtis, Scott Wilson
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$3,965
+30,500 vol $0.13 each |
30,500 | |
| Filed 2016-03-11 Tx date 2016-03-09 |
$ATE
Antibe Therapeutics Inc. |
Curtis, Scott Wilson
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$65,249
+450,000 vol $0.145 each |
450,000 | |
| Filed 2016-03-10 Tx date 2016-01-01 |
$ATE
Antibe Therapeutics Inc. |
Curtis, Scott Wilson
5 - Senior Officer of Issuer
Direct Ownership
|
Warrants
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2016-03-10 Tx date 2016-01-01 |
$ATE
Antibe Therapeutics Inc. |
Curtis, Scott Wilson
5 - Senior Officer of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2016-03-10 Tx date 2016-01-01 |
$ATE
Antibe Therapeutics Inc. |
Curtis, Scott Wilson
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|